Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2017 September;63(3) > Minerva Gastroenterologica e Dietologica 2017 September;63(3):285-92



To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Gastroenterologica e Dietologica 2017 September;63(3):285-92

DOI: 10.23736/S1121-421X.16.02322-9


language: English

The curative effect of early use of enteral immunonutrition in postoperative gastric cancer: a meta-analysis

Hu QIANG 1, Lu HANG 1, Sun Y. SHUI 2

1 The Second Clinical Medical College of Zhejiang Chinese Medicine University, Hang Zhou, China; 2 Department of General Surgery, Tongde Hospital of Zhejiang Province, Hang Zhou, China


INTRODUCTION: The clinical efficacy of early enteral immunonutrition in postoperative gastric cancer patients is uncertain. The aim of this study is to assess its clinical efficacy.
EVIDENCE ACQUISITION: Use of the search engine database incuding the PubMed, the Cochrane library, Web of Science, Medline, and Embase, which present comparative studies of early efficacy of enteral immune nutrition and standard enteral nutrition after gastric cancer operation. We used the RevMan 5.3 software to meta-analyze the CD4, CD8, CD4/CD8, the length of hospitalization, postoperative complications, and postoperative weight loss.
EVIDENCE SYNTHESIS: A total of 6 randomized control articles were included in this study, which comprised 606 patients. Among them, there were 308 cases of early postoperative enteral nutrition in patients with gastric cancer, and 298 cases were in standard enteral nutrition. Early postoperative enteral immune nutrition on seventh day of the CD4, CD8, and CD4/CD8 value greatly compared with standard enteral nutrition, CD4 (WMD=2.71, CI: 2.71~7.79, P<0.01), CD8 (WMD=2.71, CI: 2.71~7.79, P<0.01), CD4/CD8 (WMD=0.29, CI: 0.29~0.65, P<0.01). Postoperative complications occurred in patients with gastric cancer after operation (OR=0.46, CI 0.46 to 0.46, P<0.01), the postoperative weight loss (WMD=1.00, CI 1.00 to 2.82, P<0.01), length of hospitalization, and the value of early postoperative enteral immune nutrition group were lower than the group pf early standard enteral nutrition.
CONCLUSIONS: The treatment which could improve the clinical efficacy of patients should be considered for future management of postoperative gastric cancer.

KEY WORDS: Stomach neoplasms - Enteral nutrition - Immunosuppression

top of page